Warsh Fed confirmation plan hits a snag as expected nomination hearing is delayed

Warsh Fed confirmation plan hits a snag as expected nomination hearing is delayed


Kevin Warsh, Fellow in Economics at the Hoover Institution and lecturer at the Stanford Graduate School of Business, speaks during the Sohn Investment Conference in New York City, U.S., May 8, 2017.

Brendan McDermid | Reuters

The expected nomination hearing for Federal Reserve chair candidate Kevin Warsh has been delayed, a person familiar with the matter told CNBC on Thursday evening.

Warsh had been set to appear before the Senate Banking Committee on April 16. That won’t happen, but the hearing is still expected soon, the person said, requesting anonymity as the details have not been made public by the committee.

The committee’s rules require it to give a week’s notice before the hearing is held, and first it needs to collect paperwork from the nominee, including financial disclosures. The Banking Committee has yet to receive Warsh’s paperwork, three people familiar with the Senate process said.

The committee has not formally notified the hearing. The deadline for doing so is Thursday.

Warsh’s finances may be especially complicated. He is married to Estée Lauder cosmetics heir Jane Lauder, whose net worth is estimated at $1.9 billion, according to Forbes. 

Read more CNBC politics coverage

Financial disclosures filed in 2006 when Warsh was nominated for an earlier stint at the Fed listed nearly 1,200 assets, overwhelmingly held by his wife. Since leaving the Fed in 2011 he has spent 15 years working for investor Stanley Druckenmiller’s family office, where he led venture investments into tech firms including Palantir.

President Donald Trump announced Warsh’s nomination in January, succeeding Chair Jerome Powell, whose term as the Fed’s top official expires May 15. 

National Economic Council Director Kevin Hassett said in an interview to Fox Business Thursday that he was “highly confident” Warsh will be in place by the end of Powell’s term as chair. 

While the Trump administration appears confident about Warsh’s confirmation, it will be difficult for him to advance beyond a hearing unless Sen. Thom Tillis, R-N.C., backs off his opposition. Tillis is refusing to vote for any Fed nominees until the Department of Justice drops a criminal probe into Powell. Tillis and Powell have called that investigation a political campaign to undermine the Fed’s independence. 

U.S. Attorney for the District of Columbia Jeanine Pirro told CNBC Wednesday that she plans to move forward with the investigation. That leaves Warsh’s path beyond the hearing unclear.

Punchbowl earlier reported the delay to Warsh’s hearing.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source

European stocks soar amid growing optimism for Gulf peace deal
World

European stocks soar amid growing optimism for Gulf peace deal

European stocks soared on Wednesday as traders responded to reports that the U.S. and Iran are close to an agreement that will bring an end to the war. The White House expects an Iranian response on “several key points”, including a moratorium on nuclear enrichment, in the next 48 hours, Axios reported. The countries are […]

Read More
Novo Nordisk CEO: Aim is to expand weight-loss market in U.S.
World

Novo Nordisk CEO: Aim is to expand weight-loss market in U.S.

Charlotte Reed speaks with Mike Doustdar, CEO of Novo Nordisk, after the Danish comapny hiked its 2026 full-year guidance on the back of increased expectations for GLP-1 product sales. Source

Read More
Novo Nordisk stock jumps 6% after drugmaker hikes forcast as Wegovy pill sales smash forecasts
World

Novo Nordisk stock jumps 6% after drugmaker hikes forcast as Wegovy pill sales smash forecasts

People walk past a sign for Novo Nordisk’s annual general meeting at the entrance to the venue in Copenhagen, Denmark, March 26, 2026. Tom Little | Reuters Novo Nordisk hiked its annual profit guidance on Wednesday, as the drugmaker said its Wegovy weight-loss pill performed better than expected in the first three months of the […]

Read More